Novel target PCDHB2 for breast cancer osseous metastasis diagnosis and treatment
A PCDHB2, breast cancer technology, applied in the field of biomedicine, can solve the problems of lack of breast cancer bone metastasis, difficult clinical treatment, and inability to significantly improve the survival expectation of patients, and achieve the effect of inhibiting anti-anoikis and inhibiting bone metastasis.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment approach
[0049] As an embodiment, the reagent for quantifying the level of PCDHB2 mRNA is selected from primers, probes, and gene chips.
[0050] As an embodiment, the reagent for quantifying PCDHB2 protein level is selected from antibodies and protein chips.
[0051] The inventors have determined that down-regulating or inhibiting the expression of Protocadherin Beta 2 (PCDHB2) can significantly inhibit the bone metastasis of breast cancer cells in mice and inhibit the resistance of breast cancer cells to anoikis through animal in vivo and cell in vitro experiments. Apoptosis, as well as migration and invasion abilities; the above undoubtedly confirm that PCDHB2 can be specifically used as a therapeutic target for bone metastasis of breast cancer.
[0052] In the third aspect, the present invention proposes the use of PCDHB2 inhibitory reagents in the preparation of drugs for preventing, inhibiting and / or treating bone metastasis of breast cancer.
[0053] The PCDHB2 inhibitory agent...
Embodiment 1
[0059] Example 1, PCDHB2 is highly expressed in breast cancer tissue with bone metastasis
[0060] Transcript sequencing was performed on 29 collected breast cancer tissues, including 12 LumB breast cancer tissues with the same clinicopathological stage (4 cases with bone metastasis within 7 years; 8 cases without bone metastasis within 7 years), 9 The tissues of Her2 type breast cancer (3 cases with bone metastasis within 7 years; 6 cases without bone metastasis within 7 years) and 8 cases of BasL type breast cancer tissues (3 cases with bone metastasis within 7 years; 5 cases without bone metastasis within 7 years), compared Differentially expressed genes between breast cancer tissues with bone metastasis within 7 years and breast cancer tissues without bone metastasis within 7 years, found that 62 genes were up-regulated and 353 genes were down-regulated in breast cancer tissues with bone metastasis within 7 years, of which Such as figure 1 As shown, PCDHB2 was significant...
Embodiment 2
[0062] Example 2. PCDHB2 is specifically highly expressed in BasL breast cancer, and it indicates an earlier risk of bone metastasis
[0063] 472 breast cancer tissues of all types were collected, including 125 cases of LumA type, 140 cases of LumB type, 47 cases of Her2 type, 160 cases of BasL type, and 52 cases of benign breast hyperplasia for immunohistochemical analysis. The method is as follows:
[0064] After heat-treating tissue sections at 65°C for 1 hour, dewax in xylene twice for 5 minutes each time; hydrate the sections with 100% ethanol, 95% ethanol, 85% ethanol, 75% ethanol and pure water successively, 1 minute each time; After taking it out, add 3% hydrogen peroxide dropwise and incubate at room temperature for 10 minutes to inactivate endogenous peroxidase; place the slice in a container filled with EDTA pH9.0 repair solution, and repair it under high pressure in a pressure cooker for 10 minutes; Surround the tissue with a pen and rinse it with PBS buffer for 3 ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com